Cargando…

Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()

PET/CT is a commonly used modality in cancer imaging, as it can help in diagnosis, staging and assessment of treatment response in many cancer types. A better understanding of the tumor microenvironment and identification of multiple selective targets are promoting further investigation into differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Franquet, Elisa, Park, Hyesun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691399/
https://www.ncbi.nlm.nih.gov/pubmed/36439301
http://dx.doi.org/10.1016/j.ejro.2022.100455
_version_ 1784837033463644160
author Franquet, Elisa
Park, Hyesun
author_facet Franquet, Elisa
Park, Hyesun
author_sort Franquet, Elisa
collection PubMed
description PET/CT is a commonly used modality in cancer imaging, as it can help in diagnosis, staging and assessment of treatment response in many cancer types. A better understanding of the tumor microenvironment and identification of multiple selective targets are promoting further investigation into different radiotracers for diagnosis and therapy. In the past few decades many radiopharmaceuticals have emerged for specific oncologic indications providing superior detection rate than some morphologic modalities. The purpose of this review is to provide an update on the most current radiopharmaceuticals used in cancer imaging including the mechanism of action, indications and pitfalls.
format Online
Article
Text
id pubmed-9691399
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96913992022-11-26 Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications() Franquet, Elisa Park, Hyesun Eur J Radiol Open Article PET/CT is a commonly used modality in cancer imaging, as it can help in diagnosis, staging and assessment of treatment response in many cancer types. A better understanding of the tumor microenvironment and identification of multiple selective targets are promoting further investigation into different radiotracers for diagnosis and therapy. In the past few decades many radiopharmaceuticals have emerged for specific oncologic indications providing superior detection rate than some morphologic modalities. The purpose of this review is to provide an update on the most current radiopharmaceuticals used in cancer imaging including the mechanism of action, indications and pitfalls. Elsevier 2022-11-24 /pmc/articles/PMC9691399/ /pubmed/36439301 http://dx.doi.org/10.1016/j.ejro.2022.100455 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Franquet, Elisa
Park, Hyesun
Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
title Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
title_full Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
title_fullStr Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
title_full_unstemmed Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
title_short Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
title_sort molecular imaging in oncology: common pet/ct radiopharmaceuticals and applications()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691399/
https://www.ncbi.nlm.nih.gov/pubmed/36439301
http://dx.doi.org/10.1016/j.ejro.2022.100455
work_keys_str_mv AT franquetelisa molecularimaginginoncologycommonpetctradiopharmaceuticalsandapplications
AT parkhyesun molecularimaginginoncologycommonpetctradiopharmaceuticalsandapplications